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Abstract Naratriptan 2.5 mg is now an over-the-counter
drug in Germany. This should increase the interest in drug.
The GSK Trial Register was searched for published and
unpublished double-blind, randomised, controlled trials
(RCTs) concerning the use of naratriptan in migraine. Only
7 of 17 RCTs are published in full. Naratriptan 2.5 mg is
superior to placebo for acute migraine treatment in 6 RCTs,
but inferior to sumatriptan 100 mg and rizatriptan 10 mg in
one RCT each. This dose of naratriptan has no more
adverse events than placebo. Naratriptan 1 mg b.i.d. has
some effect in the short-term prophylactic treatment of
menstruation-associated migraine in 3 RCTs. In 2 RCTs,
naratriptan 2.5 mg was equivalent to naproxen sodium
375 mg for migraine-related quality of life. Naratriptan
2.5 mg (34% preference) was superior to naproxen sodium
500 mg (25% preference). Naratriptan 2.5 mg is better than
placebo in the acute treatment of migraine. The adverse
effect proﬁle of naratriptan 2.5 mg is similar to that of
placebo. The efﬁcacy of naratriptan 2.5 mg versus NSAIDs
is not sufﬁciently investigated. Naratriptan, when available
OTC is a reasonable second or third choice on the step care
ladder in the acute treatment of migraine.
Keywords Naratriptan  Unpublished clinical trials 
Migraine
Introduction
In Germany, the 5-hydroxytryptamine (5-HT)1B/1D receptor
agonist naratriptan is an over-the-counter (OTC) drug,
most likely because of its excellent tolerability [1–3]. The
time to maximum blood concentration is 2 h for oral
naratriptan, and 1.5 h for oral sumatriptan [2, 4]. The oral
bioavailability of naratriptan is 74%, and much higher than
the 14% availability of sumatriptan [4]. The elimination
half-lives of naratriptan and sumatriptan are 5.5 and 2 h,
respectively [4]. Naratriptan 2.5 mg tablets have a placebo-
like tolerability proﬁle and are associated with a low
incidence of headache recurrence [5]. Thus, the 2.5-mg
dose offers some advantages over other 5-HT1B/1D ago-
nists, and naratriptan has been called the ‘‘gentle triptan’’
[5].
In 1998, the Ethics Subcommittee of the International
Headache Society [6] stated that the ‘‘responsibility for
publication cannot be separated from the ethical responsi-
bility of the investigator’’. The Subcommittee agreed that
‘‘scientists have an ethical obligation to submit creditable
research results for publication, and should not enter into
agreements that interfere with their control over the deci-
sion to publish.’’ As a general rule, every methodologically
sound, randomised, controlled trial should be published to
allow an evaluation of the results; publication solely as an
abstract or in non-peer-reviewed supplements is unac-
ceptable [6].
Recently, I reported on six unpublished randomised
controlled trials (RCTs) with sumatriptan [7]. These RCTs
were found in the GlaxoSmithKline (GSK) Trial Register,
and I became aware of unpublished RCT with naratriptan.
Because naratriptan is now becoming an OTC drug in some
countries, a review of all RCTs is relevant. In the present
review of 17 double-blind, randomised, controlled trials
P. C. Tfelt-Hansen (&)
Department of Neurology, Danish Headache Center,
Glostrup Hospital, University of Copenhagen,
Glostrup, Denmark
e-mail: ptha@glo.regionh.dk
123
J Headache Pain (2011) 12:399–403
DOI 10.1007/s10194-011-0327-3(RCTs) in the naratriptan part of the GSK Trial Register, it
was remarkable that less than half of these RCTs were fully
published in peer-reviewed journals.
Methods
The GSK Register (http://www.gsk-clinicalstudyregister.
com/) for naratriptan, which consists of 47 phase I to phase
IV clinical studies, was searched for double-blind RCTs
with oral naratriptan for migraine treatment regardless of
the dose of naratriptan. The following data were extracted
from the summary reports of each double-blind RCT (see
Table 1): (1) doses of naratriptan, doses of other drugs, and
the use of placebo; (2) number of centers; (3) total number
of patients; (4) full publication (yes/no); (5) publication as
an abstract (yes/no); and (6) reported results (either from
the summary or from the full publication).
Results
All RCTs were multicenter RCTs (Table 1). Twelve out of
17 RCTs [8–24] were placebo-controlled, and in 5 RCTs
[10, 20–22, 24] there was a presumably active comparator.
The median number of participating centers per RCT
was 51 (range 10–152). In these 17 RCTs, the median
number of patients was 236 (range 168–1,141). Seven
RCTs [11, 14, 15, 17, 19, 20, 23] were fully published in a
peer-reviewed journal. Ten RCTs [12–17, 19, 21, 23, 28]
were published as an abstract, and 6 RCTs [8–10, 18, 22,
23] were never published.
Naratriptan 2.5–10 mg was superior to placebo for acute
migraine treatment in all 6 RCTs in adults [11, 14, 15, 17,
21, 23], whereas naratriptan 2.5 mg was not superior to
placebo in adolescents [16]. In 3 RCTs [11–13], short-term
prophylaxis with naratriptan 1 mg b.i.d was superior to
placebo for menstruation-associated migraine (MAM). In 2
RCTs [8, 9], naratriptan 2.5 mg was equivalent to naproxen
sodium 375 mg for migraine-related quality of life. Nara-
triptan 2.5 mg (34% preference) was superior to naproxen
sodium 500 mg (25% preference) [10]. Naratriptan 2.5 mg
[66% headache relief (HR) at 4 h] was inferior to suma-
triptan 100 mg (76% HR at 4 h) in one RCT [21], whereas
the higher 10-mg dose of naratriptan (80% HR at 4 h) was
quite similar to sumatriptan 100 mg (80% HR at 4 h) [24].
Discussion
A recent review on reporting bias in clinical trials [25]
concluded that ‘‘the prevalence of incomplete outcome
reporting is high’’. In addition, when all randomised
controlled trials (RCTs) are not published, it results in
publication bias, which can be considerable and can distort
available evidence [26].
Publication of well-conducted RCTs is primarily the
responsibility of the clinical investigators. However, all the
RCTs on naratriptan were multicenter trials (range 10–152
centers) and the pharmaceutical company, GSK was most
likely fully in control of both the conduct and the publi-
cation of the RCTs. Seven pivotal RCTs [11, 14, 15, 17, 19,
21, 23] were fully published, but one was not [21] (see
Table 1). The reasons for not publishing the 10 other RCT
in full remains unknown.
Notably, the 2,729 patients included in the fully pub-
lished RCTs represent less than half (45%) of the 6,112
patients participating in the naratriptan trial program.
When migraine patients were recruited to an RCT, which
may include placebo or a less effective drug, for up to 4 h,
it should be an obligation to publish the results in a
peer-reviewed journal. The conduct of RCTs solely for
registration purposes, without full publication, should be
avoided. The data presented in this review should be and
are now in the public domain. They conﬁrm, as expected,
that naratriptan is superior to placebo as was also found in
meta-analyses [1–3]. It should be noted, however, that
headache relief (a decrease in headache from moderate or
severe to none or mild) was ﬁrst measured after 4 h
because naratriptan is generally held to be a slow-acting
triptan [5]. The ‘‘slow onset of action’’ (a delay in onset) of
naratriptan was apparently conﬁrmed in one RCT (see
Fig. 1)[ 21]. After 2 h, the headache relief for patients
taking sumatriptan 100 mg and for naratriptan 2.5 mg were
59 and 50%, respectively. After 2 h, the curves for head-
ache relief were parallel, with the endpoint headache relief
at 4 h for sumatriptan 100 mg at 76% and naratriptan
2.5 mg at 66%. Thus, it is difﬁcult to judge the speed of
onset of action of the two drugs when the ﬁnal endpoints
are different [27]. In contrast, in an RCT using the higher
10-mg dose of naratriptan versus 100 mg sumatriptan, the
endpoint of 4-h headache relief was similar, at 80%, for
both groups [24]. As shown in Fig. 2, there is no difference
in the ‘‘onset of action’’ when equipotent doses of the two
drugs are used. Thus, naratriptan is not a slow-acting drug
per se.
Naratriptan 1 mg b.i.d was superior to placebo for short-
term prophylaxis of MAM in 3 RCTs, and naratriptan
halved the MAM in one RCT [19], whereas in 2 RCTs 36%
were without MAM versus 27% for placebo [12, 13]; these
results suggest a modest effect of short-term prophylaxis
with naratriptan in MAM.
Naratriptan was evaluated in 3 RCT versus the NSAID,
naproxen sodium [8–10] (see Table 1). In two RCTs,
naratriptan was not superior to naproxen sodium 375 mg
for migraine-related quality of life [8, 9]. In one RCT, more
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123Table 1 Overview of 17 randomised, controlled trials with oral naratriptan for migraine treatment found in the GSK Trial Register (http://www.
gsk-clinicalstudyregister.com/)
Drugs used [reference] (protocol code in GSK register) Number of
centers
Total number
of patients
(study design)
Full
publication
Abstract(s) Results
Na 2.5 mg vs. naproxen sodium (NS) 275 mg [8]
[S2WA4003]
19 168 (P) – – Na and NS had similar effect on
MRQL
Na 2.5 mg vs. NS 275 mg [9] [S2WA4004] 20 171 (P) – – Na and NS had similar effect on
MRQL
Na 2.5 mg vs. NS 500 mg [10] [S2W40010]
a 70 456 (C) – – Preference: Na (34%)[NS
(26%)
c
Na 2.5 mg vs. PL in mild MAM [11] [S2W40031] 152 229 (P) ? – Na (58% headache relief)[PL
(30% headache relief)
Na 1 mg b.i.d. vs. placebo for MAM [12] [S2W40012] 51 187 (P) – ? Without MAM: Na 38%[PL
29%
Na 1 mg b.i.d. vs. PL [13] [S2W40024] 61 236 (P) – ? Without MAM: Na 34%[PL
24%
Na 0.1, 0.25, 1.0, 2.5 mg vs. PL [14] [S2WA3001] 54 613 (P) ??Na 1 mg (50%) and 2.5 mg
(60%)[PL (34%) for headache
relief at 4 h
Na 0.25, 1.0, and 2.5 mg vs. PL [15] [S2WA3003] 50 602 (C) ??Na 1.0 mg (57%) and 2.5 mg
(68%)[PL (33%) for headache
relief after 4 h
Na 0.25, 1.0, and 2.5 mg vs. placebo in adolescent
migraine [16] [S2WA3012]
44 300 (P) – ? Na 0.25 mg (72%), 1.0 mg (67%)
and 2.5 mg (64%) were similar to
PL (65%) for headache relief
after 4 h
Na 2.5 mg vs. PL in pt not responding to sumatriptan
[17] [S2WA4002]
57 206 (382) (P)
b ??Na (47%)[PL (20%) for
headache relief after 4 h
Na 2.5 mg b.i.d. vs. PL in transformed migraine [18]
[S2WA4005]
11 170 (P) – – Na (13%) similar to PL (17%) for
no headache on days 13 and 14.
Na 1 mg and 2.5 mg b.i.d. vs. PL in MAM [19]
[S2WA4006]
18 206 (P) ??Median MAM over 4
menstruation: PL = 4,
1m g= 2, 2.5 mg = 3. Na
1.0 mg\PL (p = 0.011)
Na 2.5 mg vs. sumatriptan 100 mg in recurrence prone
patients [20] [S2WB3011]
34 236 (C) ??24 h overall efﬁcacy: Na (40%)
similar to sumatriptan (35%)
Na 0.1 mg, 0.25 mg, 1.0 mg, and 2.5 mg vs.
sumatriptan 100 mg vs. placebo [21] [S2WB3002]
113 1,141 (942) (P)
c - ? Na 1.0 mg (52%) and 2.5 mg
(66%)[PL (27%) for headache
relief at 4 h, sumatriptan (76%)
was superior to all Na doses
Na 2.5 mg vs. sumatriptan 50 mg in patients who
relapse from sumatriptan (100 mg orally or 6 mg
subcutaneously) [22] [S2WB4001]
66 464 (C) – – Satisfaction with overall
effectiveness: very satisﬁed or
satisﬁed: Na (52%) similar to
sumatriptan (48%)
Na 5 mg and 10 mg vs. placebo [23] [S2WB2003] 10 90 (P) – – Headache relief at 4 h: Na 5 mg
(89%) and 10 mg (72%)[PL
(33%)
Na 1, 2.5, 5, 7.5, and 10 mg vs. sumatriptan 100 mg and
vs. PL [24] [S2WB2004]
74 637 (P) ??For headache relief at 4 h all doses
of Na (64%, 63%, 65%, 80%, and
80%) were superior to PL (39%).
Na 7.5 mg and 10 mg were
similar to sumatriptan 100 mg
(80%), which was superior to Na
1, 2.5, and 5 mg
C crossover, P parallel group, Na naratriptan, NS naproxen sodium, MRQL migraine-related quality of life, PL placebo, MAM menstruation-associated
migraine
a Patients dissatisﬁed with simple analgesics in the treatment of migraine attacks
b Number of patients treated with a single-blind dose of sumatriptan 50 mg
c Number of patients completing and treating 3 attacks
d Complete headache relief after 4 h was 39% in both treatment groups
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123patients (34%) preferred naratriptan than naproxen sodium
500 mg (25%) [10]. It is unclear why naratriptan 2.5 mg is
similar to naproxen 375 mg but better than the higher
500-mg dose of naproxen sodium. It may be due to the
design of the studies.
In conclusion, the investigators are obligated to the
migraine patients participating in the trials, who often
endured placebo administration for 4 h, to ensure that the
results of well-conducted, randomised trials are published
in peer-reviewed journals. This can be difﬁcult when there
are multicenter trials with many investigators, and I suggest
that investigators choose a publication committee among
themselves, e.g. one from each country or each region.
In this review, all double-blind RCTs with oral nara-
triptan in the treatment of migraine are presented [8–24].
This does not change the overall picture of an effective and
well-tolerated triptan [3]. Whereas naratriptan is superior to
placebo, the 2.5-mg dose chosen is less effective than
sumatriptan 100 mg (2 and 4 h) (see Table 1), and riza-
triptan 10 mg (2 h) [28]. The inferiority of naratriptan
versus most other triptans at 2 h has been shown in meta-
analyses [1, 2, 4], and this has been ascribed to a slow
action of naratriptan [5]. The apparent slow onset of
naratriptan 2.5 mg is, however, a matter of dose (see
above).
When naratriptan 2.5 mg became an OTC drug, the
question of its efﬁcacy compared with other OTC drugs
and NSAIDs became relevant. Naratriptan was not com-
pared with paracetamol or aspirin, which in an effervescent
form (52% headache relief) was found to have similar
efﬁcacy as sumatriptan 50 mg (46% headache relief) in a
meta-analysis [28]. There are 2 RCTs comparing nara-
triptan 2.5 mg with naproxen sodium 275 mg (Table 1).
Unfortunately, no placebo-control was used in the RCTs,
but no differences between the active drugs were observed.
Patients’ preference for naratriptan (34%) was marginally
superior to naproxen sodium (26%) (Table 1) in patients
dissatisﬁed with simple analgesics [10]. What is missing is
a comparative RCT of naratriptan 2.5 mg (50% headache
relief Table 1), and lysine acetylsalicylate and metoclo-
pramide, which showed headache relief of 56% in 2 RCTs
[29, 30]. Until such comparative RCTs become available,
one cannot, based on the available evidence, recommend
what migraine patients should try next when they are dis-
satisﬁed with simple analgesics. Naratriptan is a reasonable
OTC choice as second or third choice on the step care
ladder.
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